
    
      The trial is a Phase III, multinational, multicentre, controlled, randomised open-label
      trial. It will involve 520 advanced pancreatic cancer patients. Patients will be randomly
      assigned to receive Gemcitabine alone or GV1001 plus GM-CSF followed by addition of
      Gemcitabine at the time of 1st progression of disease. The experimental treatment is given
      prior to the current standard treatment in 50% of the patients.
    
  